Could a daily pill replace frequent blood tests for heart valve patients?
NCT ID NCT07456085
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares rivaroxaban, a newer blood thinner that doesn't need regular lab monitoring, to the standard drug warfarin in 60 adults with mechanical heart valves. The goal is to see if rivaroxaban can safely prevent blood clots and bleeding complications. Participants will take rivaroxaban once or twice daily along with aspirin, and be followed for one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivaroxaban
What this could lead to
If successful, this could offer a simpler, more accessible blood-thinning option for people with mechanical heart valves, reducing the need for frequent lab tests.
What could go wrong
This is a small, early-phase study with only 60 participants, so results may not apply to everyone. Rivaroxaban may not prevent blood clots as well as warfarin in this setting, and bleeding risks remain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VALVULAR HEART DISEASE PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rawalpindi Institute of Cardiology
Rawalpindi, Punjab Province, 46000, Pakistan